在软组织伤口愈合过程中,β-腺受体抑制剂的机制和应用
Shasha Jia1,2, Xueya Wang1,2, Guowei Wang3
1Department of Oral Implantology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, People's Republic of China.
Medicinal research reviews
|July 20, 2023
概括
β-抑制剂可以通过抑制β-上腺素受体 (β-ARs) 来改善软组织伤口愈合. 这些药物可以加速各种伤口的愈合,但它们的机制需要进一步研究.
科学领域:
- 药理学 药理学是指药理学的学科.
- 伤口治愈研究研究 伤口治愈研究
- 细胞生物学 细胞生物学
背景情况:
- 软组织损伤触发了儿科胺的释放,激活了β-上腺素受体 (β-ARs) 并破坏了伤口的修复.
- 已知β-阻断剂可以抑制β-ARs,这表明它在调节伤口愈合过程中的作用.
研究的目的:
- 要总结β-阻断剂在软组织伤口愈合中的多方面的作用.
- 探索β-阻断剂在伤口修复中的临床应用和潜在机制.
主要方法:
- 关于研究β-阻断剂对各种软组织损伤的影响的文献综述.
- 分析包括炎症,细胞迁移,血管生成和细菌影响在内的机制.
主要成果:
- β-阻断剂通过减少炎症和高代谢来加速急性/慢性皮肤病变,性血管瘤和严重的热损伤的愈合.
- 对角膜伤口愈合的影响是可变的,可能促进或延迟再生.
- β-阻断剂影响状细胞迁移,再上皮化,伤口收缩和血管生成.
结论:
- β-阻断剂在加速软组织伤口愈合方面具有显著的潜力.
- 进一步研究β抑制剂的精确机制对于优化其临床使用至关重要.
- 临床应用范围包括急性伤口,慢性病变,烧伤以及婴儿血瘤和角膜损伤等特定疾病.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
892
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
892
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
669
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
669
Adrenergic Antagonists: ɑ and β-Receptor Blockers
517
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
517
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
888
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
888
Adrenergic Receptors: β Subtype
1.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364


